Radiopharm Theranostics received approval from the Hollywood Private Hospital in Perth, Western Australia, to become the second Australian trial site for its RAD 204 Phase 1 therapy targeting PD-L1-positive non-small cell lung cancer.
The clinical-stage biopharmaceutical company will soon begin recruiting 21 patients for the study, which aims to evaluate the safety and efficacy of its novel radiotherapy, 177Lu-RAD 204.
The trial will also commence at the Princess Alexandra Hospital in Brisbane, Queensland.
Adding a second site is expected to accelerate patient recruitment due to increased accessibility.
Oncology care provider GenesisCare supports the project.